¼¼°èÀÇ »ó½Ç¼ººó¹Ú ½ÃÀå
Supraventricular Tachycardia
»óǰÄÚµå : 1798267
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ »ó½Ç¼ººó¹Ú ½ÃÀåÀº 2030³â±îÁö 10¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6¾ï 4,880¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ »ó½Ç¼ººó¹Ú ½ÃÀåÀº 2030³â¿¡´Â 10¾ï ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Atrioventricular Nodal Re-entrant Tachycardia´Â CAGR 10.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4¾ï 8,420¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Atrioventricular Reciprocating Tachycardia ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 6.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 7,680¸¸ ´Þ·¯, Áß±¹Àº CAGR 13.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »ó½Ç¼ººó¹Ú½ÃÀåÀº 2024³â¿¡ 1¾ï 7,680¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 13.4%·Î, 2030³â±îÁö 2¾ï 3,140¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.0%¿Í 8.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ »ó½Ç¼ººó¹Ú ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»ó½É½Ç¼º ºó¸ÆÀ̶õ ¹«¾ùÀ̸ç, ¿Ö Áß¿äÇѰ¡?

»ó½É½Ç¼º ºó¸Æ(SVT)Àº ½ÉÀåÀÇ ½É½Ç »óºÎ¿¡¼­ ¹ß»ýÇÏ´Â ºÎÁ¤¸ÆÀÇ ÀÏÁ¾À¸·Î ºñÁ¤»óÀûÀ¸·Î ºü¸¥ ½ÉÀå ¹Úµ¿ ¸®µëÀ» ÀÏÀ¸ÄÑ ½ÉÀå ±â´ÉÀ» ÇöÀúÇÏ°Ô ¹æÇØÇÏ´Â ºÎÁ¤¸ÆÀ» ¸»ÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î »ý¸íÀ» À§ÇùÇÏÁö´Â ¾ÊÁö¸¸, SVT´Â ȯÀÚ¸¦ °íÅ뽺·´°í ¼è¾àÇÏ°Ô ¸¸µé ¼ö ÀÖÀ¸¸ç, Á¾Á¾ ½É°èÇ×Áø, Çö±âÁõ, ÈäÅë, ÇÇ·Î µîÀÇ Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. SVT¿¡´Â ½É¹æ °áÀý ÀçÁøÀÔ¼º ºó¸Æ(AVNRT), ½É¹æ ¿Õº¹¼º ºó¸Æ(AVRT), ½É¹æ ºó¸Æ µîÀÇ ÇÏÀ§ À¯ÇüÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÎÁ¤¸ÆÀº Á¾Á¾ Àü±âÀû ÀçÁøÀÔ È¸·Î ¶Ç´Â ½ÉÀå Á¶Á÷ÀÇ ºñÁ¤»óÀûÀÎ ÀÚµ¿¼º¿¡ ÀÇÇØ À¯¹ßµË´Ï´Ù.

SVTÀÇ ÀÓ»óÀû Á߿伺Àº ³ôÀº Àç¹ß·ü, ¿¹Ãø ºÒ°¡´ÉÇÑ ¹ßº´, ƯÈ÷ °í·ÉÀÚ ¹× ÇÕº´ÁõÀ» °¡Áø Áý´Ü¿¡¼­ »îÀÇ ÁúÀ» ÀúÇØÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. SVTÀÇ À¯º´·üÀº Àü ¼¼°è¿¡¼­ Áõ°¡Çϰí ÀÖÀ¸¸ç, Àα¸ °í·ÉÈ­, ½ÉÇ÷°ü °ËÁø Áõ°¡, °íÇ÷¾Ð ¹× ±¸Á¶Àû ½ÉÀåÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ±× ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ±Þ¼º ¿¡ÇǼҵå´Â Á¾Á¾ ¹ÌÁֽŰæ Á¶ÀÛÀ̳ª ¾Æµ¥³ë½Å°ú °°Àº ¾à¹°·Î Á¾½Ä½Ãų ¼ö ÀÖÁö¸¸, ¸¹Àº ȯÀÚµéÀº Àå±âÀûÀÎ °ü¸® Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. À̸¦ À§ÇØ Àü±â»ý¸®ÇÐ, ÀåÄ¡¸¦ ÀÌ¿ëÇÑ ÁßÀç, ¾à¹° Ä¡·á µîÀÇ ±â¼ú Çõ½ÅÀÌ Àý½ÇÈ÷ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

Áø´Ü ¹× Ä¡·á ÇÁ·ÎÅäÄÝÀº ±â¼ú°ú ÇÔ²² ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

SVTÀÇ Áø´Ü°ú Ä¡·á´Â Á¤±³ÇÑ Áø´Ü Åø¿Í ÁßÀç ±â¼úÀÇ ÅëÇÕÀ¸·Î Å©°Ô ¹ßÀüÇß½À´Ï´Ù. ȦÅÍ ¸ð´ÏÅÍ, À̽ÄÇü ·çÇÁ ¸®ÄÚ´õ, ÈÞ´ë¿ë ½ÉÀüµµ ÀåÄ¡ µîÀ¸·Î Áø·á Áß ¹ß°ßµÇÁö ¾ÊÀ» ¼ö ÀÖ´Â ÀϽÃÀûÀÎ SVT ¿¡ÇǼҵ带 Á¤È®ÇÏ°Ô Æ÷ÂøÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ºñħ½ÀÀû ¸ÅÇÎ ±â¼úÀ» ÅëÇØ Àü±â»ý¸®ÇÐÀÚµéÀº ºÎÁ¤¸Æ ¹ß»ý º´¼ÒÀÇ À§Ä¡¸¦ ³î¶ó¿ï Á¤µµ·Î Á¤È®ÇÏ°Ô ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾î º¸´Ù Á¤¹ÐÇÑ Ä¡·áÀÇ Åä´ë¸¦ ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

ƯÈ÷ Ä«Å×ÅÍ ÀýÁ¦¼úÀº ÃÖ¼Ò Ä§½ÀÀûÀ̰í Á¾Á¾ ±Ùº»ÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇÔÀ¸·Î½á SVT °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. 3D Àü±âÇØºÎÇÐ ¸ÅÇÎ, ½ÉÃÊÀ½ÆÄ, ¿ø°Ý Àڱ⠳׺ñ°ÔÀ̼ǰú °°Àº ±â¼ú Çõ½ÅÀ¸·Î ÃֽŠÀýÁ¦ ½Ã½ºÅÛÀº ÇöÀç ´õ ³ôÀº È¿°ú, ´õ ³·Àº Àç¹ß·ü, ´õ ³ôÀº ¾ÈÀü¼ºÀ» ½ÇÇöÇϰí ÀÖ½À´Ï´Ù. ¾à¸®ÇÐÀû Ãø¸é¿¡¼­´Â ºÎÁ¤¸Æ À§ÇèÀ» °¨¼Ò½ÃŲ »õ·Î¿î Ç׺ÎÁ¤¸ÆÁ¦°¡ ÀÓ»óÀûÀ¸·Î Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. À¯ÀüÀû ¼ÒÀÎ, ÇØºÎÇÐÀû º¯ÀÌ, µ¿¹Ý ÁúȯÀ» °í·ÁÇÑ °³Àκ° ¸ÂÃã Ä¡·á Á¢±Ù¹ýµµ º¸±ÞµÇ°í ÀÖÀ¸¸ç, SVT Ä¡·á¿¡ ÀÖÀ¸¸ç, º¸´Ù °³ÀÎÈ­µÈ Ç¥ÁØ Ä¡·áÀÇ ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù.

SVT Ä¡·áÁ¦ÀÇ ¼¼°è Á¤¼¼¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ½ÃÀå µ¿ÇâÀº?

ÀÇ·áÀÇ µðÁöÅÐÈ­, ½ÉÇ÷°ü°è¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÷´Ü ½ÉÀå Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë°¡ SVT ½ÃÀå Àü¸ÁÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ½ÉÀüµµ ¸ð´ÏÅÍ¿Í ¸ð¹ÙÀÏ Çコ ¾ÛÀÇ º¸±ÞÀº ƯÈ÷ ¿Ü·¡ ȯÀÚ³ª Áö¹æÀÇ Á¶±â Áø´Ü¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ ÀåÄ¡µéÀº ½Ç½Ã°£ ¸®µë ÃßÀû°ú ½ÉÀå Àü¹®ÀÇ¿ÍÀÇ µ¥ÀÌÅÍ °øÀ¯¸¦ ÅëÇØ Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. Ŭ¶ó¿ìµå Ç÷§Æû ¹× AI ¾Ë°í¸®Áò°úÀÇ ÅëÇÕÀ» ÅëÇØ ºÎÁ¤¸Æ °¨Áö Á¤È®µµ¸¦ Çâ»ó½Ã۰í, ȯÀÚº° µ¥ÀÌÅÍ ÆÐÅÏ¿¡ ±â¹ÝÇÑ ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ ÀÓ»óÀÇ¿¡°Ô Á¦°øÇÕ´Ï´Ù.

Áø´Ü°ú º´ÇàÇÏ¿©, Àåºñ Á¦Á¶¾÷üµéÀº °³¼±µÈ ¿¡³ÊÁö °ø±Þ ½Ã½ºÅÛ, ½Ç½Ã°£ Çǵå¹é ¸ÞÄ¿´ÏÁò, AI Áö¿ø ½Ã¼ú °¡À̵带 °®Ãá Â÷¼¼´ë ÀýÁ¦¿ë Ä«Å×ÅÍ °³¹ßÀ» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Ã¼úÀÇ ÆíÂ÷¿Í ¹æ»ç¼± ÇÇÆøÀ» ÁÙÀ̱â À§ÇØ ·Îº¿ ³×ºñ°ÔÀÌ¼Ç ½Ã½ºÅÛµµ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÀǾàǰ Ãø¸é¿¡¼­´Â Àå±âÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â ½É¹Ú¼ö ¹× ¸®µë Á¶Àý ¾à¹° °³¹ß¿¡ ´Ù½Ã ÇÑ ¹ø ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº »õ·Î¿î Ç׺ÎÁ¤¸ÆÁ¦ ¹× ÀýÁ¦ ÀåÄ¡ÀÇ ½ÂÀÎ °æ·Î¸¦ °£¼ÒÈ­ÇÏ¿© ½Å¼ÓÇÑ ÀÓ»ó µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½ÉÀå ÀÎÇÁ¶ó°¡ ¹ÌºñÇÑ Áö¿ª¿¡¼­´Â ¹Î°ü Çù·Â°ú À̵¿½Ä Àü±â»ý¸®ÇÐÀû Ä¡·á Àåºñ°¡ Ä¡·á °ÝÂ÷¸¦ ÇØ¼ÒÇϰí Ä¡·á Á¢±Ù¼ºÀ» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

»ó½É½Ç¼º ºó¸Æ ½ÃÀå ¼ö¿ä Áõ°¡ ¿äÀÎÀº ¹«¾ùÀΰ¡?

»ó½É½Ç¼º ºó¸Æ ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»óÀû ¿ä±¸, ±â¼ú Çõ½Å, ÀÇ·á ÀÎÇÁ¶ó È®Àå°ú °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ °í·ÉÈ­ Àα¸ Áõ°¡·Î ÀÎÇØ ½É¹æ¼¼µ¿ Áø´ÜÀÌ ±ÞÁõÇϰí ÀÖÀ¸¸ç, º¸´Ù È¿°úÀûÀÎ Àå±âÀû Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. °íÇ÷¾Ð, ´ç´¢º´, ºñ¸¸ Áõ°¡´Â ºÎÁ¤¸Æ °¨¼ö¼º Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Ä¡·á Àα¸¸¦ ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù.

¶ÇÇÑ Àü±â»ý¸®ÇÐÀû ±â¼ú, ƯÈ÷ °íÁÖÆÄ ¹× ³Ãµ¿ ÀýÁ¦ ½Ã½ºÅÛÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÎÅͺ¥¼Ç Ä¡·á°¡ ´õ¿í Ä£¼÷ÇÏ°í ¼º°øÀûÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¿þ¾î·¯ºí ½ÉÀå ¸ð´ÏÅ͸µ ±â±âÀÇ µµÀÔÀº Á¶±â Áø´ÜÀ» ÃËÁøÇϰí, ½Ã¼ú ÀÇ·Ú¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¼±Áø±¹°ú ½ÅÈï °æÁ¦±¹ ¸ðµÎ¿¡¼­ ½ÉÀå Àü¹®¼¾ÅÍÀÇ °³¹ß°ú ¼÷·ÃµÈ Àü±â»ý¸®ÇÐÀÚÀÇ È®º¸°¡ ÀýÁ¦¼ú ¼­ºñ½ºÀÇ È®ÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² º¸´Ù ¾ÈÀüÇÑ Ç׺ÎÁ¤¸ÆÁ¦¿¡ ÃÊÁ¡À» ¸ÂÃá ÀǾàǰÀÇ ¿¬±¸°³¹ß°ú ½É¹Ú¼ö Á¶ÀýÀ» À§ÇÑ º¹ÇÕÁ¦ÀÇ °¡¿ë¼ºÀÌ ¾à¹° Ä¡·á ºÐ¾ß¿¡ Ȱ·ÂÀ» ºÒ¾î³Ö°í ÀÖ½À´Ï´Ù.

µðÁöÅÐ ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¿Í ÇÔ²² ½ÉÇ÷°ü°è ÁúȯÀÇ ÀÌȯÀ²À» ³·Ãß±â À§ÇÑ Á¤ºÎÀÇ ±¸»óµµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »óȯ Á¤Ã¥ÀÇ °³¼±°ú ÀýÁ¦¼úÀÌ ±¹°¡ º¸ÇèÁ¦µµ¿¡ ÀÓº£µðµåµÇ¸é¼­ ´õ ¸¹Àº ȯÀÚµéÀÌ °áÁ¤ÀûÀÎ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸¶Áö¸·À¸·Î ºÎÁ¤¸Æ°ú ÃֽнÉÀå Ä¡·á¹ýÀÇ ¾ÈÀü¼º¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Æí°ßÀÌ ÁÙ¾îµé°í Àû±ØÀûÀÎ °Ç°­°ü¸® ÇൿÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, ½É¹æ¼¼µ¿, ±âŸ À¯Çü), Ä¡·á(¾à¹° ¿ä¹ý, °íÁÖÆÄ Ä«Å×ÅÍ ÀýÁ¦, ¼ö¼ú), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, Áø´Ü ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Supraventricular Tachycardia Market to Reach US$1.0 Billion by 2030

The global market for Supraventricular Tachycardia estimated at US$648.8 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Atrioventricular Nodal Re-entrant Tachycardia, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$484.2 Million by the end of the analysis period. Growth in the Atrioventricular Reciprocating Tachycardia segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$176.8 Million While China is Forecast to Grow at 13.4% CAGR

The Supraventricular Tachycardia market in the U.S. is estimated at US$176.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$231.4 Million by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Supraventricular Tachycardia Market - Key Trends & Drivers Summarized

What Exactly Is Supraventricular Tachycardia and Why Does It Matter?

upraventricular Tachycardia (SVT) refers to a group of arrhythmias that originate above the ventricles in the heart, causing abnormally fast heart rhythms that can significantly disrupt cardiac function. Though not typically life-threatening, SVT can be distressing and debilitating for patients, often causing symptoms such as palpitations, dizziness, chest pain, and fatigue. The condition includes several subtypes such as atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular reciprocating tachycardia (AVRT), and atrial tachycardia. These arrhythmias are often triggered by electrical re-entry circuits or abnormal automaticity in cardiac tissue.

The clinical significance of SVT lies in its high recurrence rate, unpredictable onset, and the potential to impair quality of life, especially in elderly and comorbid populations. The prevalence of SVT is increasing globally, partly due to aging populations, increased cardiovascular screening, and higher rates of hypertension and structural heart disease. While acute episodes can often be terminated with vagal maneuvers or medications like adenosine, many patients require long-term management strategies. This has created a strong demand for innovations in electrophysiology, device-based interventions, and pharmacological therapy.

How Are Diagnosis and Treatment Protocols Evolving with Technology?

he diagnosis and treatment of SVT have advanced considerably with the integration of sophisticated diagnostic tools and interventional techniques. Holter monitors, implantable loop recorders, and mobile ECG devices have enabled the accurate capture of transient SVT episodes that might otherwise go undetected during clinic visits. Non-invasive mapping technologies are helping electrophysiologists localize arrhythmogenic foci with remarkable precision, laying the foundation for more targeted treatments.

Catheter ablation, in particular, has revolutionized SVT management by offering a minimally invasive, often curative solution. Powered by innovations in 3D electroanatomical mapping, intracardiac echocardiography, and remote magnetic navigation, modern ablation systems now offer improved efficacy, lower recurrence rates, and enhanced safety profiles. On the pharmacological front, newer antiarrhythmic agents with reduced proarrhythmic risk are entering clinical use. Personalized therapy approaches that factor in genetic predisposition, anatomical variations, and comorbid conditions are also gaining traction, paving the way for a more individualized standard of care in SVT treatment.

What Market Trends Are Influencing the Global SVT Therapeutics Landscape?

ealthcare digitization, rising cardiovascular awareness, and growing access to advanced cardiac care are reshaping the SVT market landscape. The proliferation of wearable ECG monitors and mobile health apps is empowering early diagnosis, particularly in outpatient and rural settings. These devices allow real-time rhythm tracking and data sharing with cardiologists, enabling timely interventions. Integration with cloud platforms and AI algorithms is also improving arrhythmia detection accuracy and providing clinicians with actionable insights based on patient-specific data patterns.

Parallel to diagnostics, device manufacturers are developing next-generation ablation catheters with improved energy delivery systems, real-time feedback mechanisms, and AI-assisted procedural guidance. Robotic navigation systems are also being explored to reduce procedural variability and radiation exposure. On the pharmaceutical front, there's renewed focus on developing rate- and rhythm-control medications with better tolerability for long-term use. Regulatory bodies are streamlining approval pathways for novel antiarrhythmic drugs and ablation devices, encouraging rapid clinical adoption. In regions with underdeveloped cardiac infrastructure, public-private partnerships and mobile electrophysiology units are helping close treatment gaps and increase procedural accessibility.

What’s Fueling the Rising Demand in the Supraventricular Tachycardia Market?

he growth in the supraventricular tachycardia market is driven by several factors linked to clinical need, technological innovation, and healthcare infrastructure expansion. The increasing prevalence of cardiovascular diseases-particularly among aging populations-is leading to a surge in SVT diagnoses, necessitating more effective long-term treatment options. Rising rates of hypertension, diabetes, and obesity are contributing to higher arrhythmia susceptibility, further expanding the treatment population.

Moreover, the rapid advancement of electrophysiology technologies-especially radiofrequency and cryoablation systems-is making interventional treatment more accessible and successful. The adoption of wearable cardiac monitoring devices is driving early diagnosis and increasing procedural referrals. Growth in cardiac specialty centers and the availability of trained electrophysiologists in both developed and emerging economies are supporting the expansion of ablation services. In parallel, pharmaceutical R&D focused on safer antiarrhythmic drugs and the availability of fixed-dose combinations for rate control are boosting pharmacotherapy segments.

Government initiatives aimed at reducing cardiovascular morbidity, alongside investments in digital health infrastructure, are also playing a critical role. Reimbursement policy improvements and inclusion of ablation in national insurance programs are encouraging more patients to pursue definitive treatments. Lastly, increasing public awareness about arrhythmias and the safety of modern cardiac procedures is reducing stigma and driving proactive healthcare behavior-all of which are fueling robust growth across the SVT diagnostics and therapeutics market.

SCOPE OF STUDY:

The report analyzes the Supraventricular Tachycardia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation, Other Types); Treatment (Medications, Radiofrequency Catheter Ablation, Surgery); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â